DeZwarteRidder schreef op 30 juni 2015 21:31:
In a report published Tuesday, BofA Merrill Lynch analyst Tazeen Ahmad upgraded the rating on BioCryst Pharmaceuticals, Inc.
from Neutral to Buy, while raising the price target from $12 to $19.
Analyst Tazeen Ahmad commented that BCX7353 is a 1x/day drug with the "potential for improved bioavailability and potency." If approved, this drug could take market share from the 9-15 pill per day regimen for the first generation '4161 in HAE treatment.
"We raise our probability of approval for ‘7353 to 40% (from 25% given validation of the plasma kallikrein target by both ‘4161 and competitor product (DX-2930, subQ injectiononce every two weeks) and now attribute ~$13/share (previously near zero) for this product," the report stated.
Ahmad cited Phase 1 PK/PD data in healthy volunteers for ‘7353, which is expected in 3Q15, as the "next key catalyst" for BioCryst's shares.
In the report BofA Merrill Lynch noted, "Pre-clinical data showed its PK profile is superior to ‘4161. Based on those results, BCRX moved the drug into humans with a once per day dosing regimen in May. We expect safety (e.g., off target effects) will be the focus of this study and see a high likelihood of this trial producing positive results."
Ahmad adds that the US market could expand with more patients seeking treatment, as a result of the "more dosing friendly regimen" from Dyax Corp.
and Biocryst.
www.benzinga.com/analyst-ratings/anal...